How much does late stage glaucoma cost?

Article

Late stage glaucoma is associated with considerable health and social care costs and a lower visual acuity (VA) is also predictive of a lower quality of life, according to John Thygesen from University Hospital Copenhagen, Denmark and colleagues from France, the UK and Germany.

Late stage glaucoma is associated with considerable health and social care costs and a lower visual acuity (VA) is also predictive of a lower quality of life, according to John Thygesen from University Hospital Copenhagen, Denmark and colleagues from France, the UK and Germany.

In order to estimate the societal costs and quality of life among patients with late stage primary open angle glaucoma (POAG), the charts of 162 such patients from Germany, France, the UK and Denmark were reviewed and patients interviewed.

Mean VA was 0.28 and 0.11 in the best and worst eye, respectively. Annual health maintenance costs were €830, excluding costs of surgery, whilst costs of devices and of home care averaged €2,045 and €2,703 per patient per year, respectively. The average quality of life score was 0.67 and the best predictor of quality of life was found to be visual acuity in the patient's best eye.

The study clearly demonstrates that late stage glaucoma is associated with considerable health and social care costs.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.